Wheel vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wheel is a telehealth infrastructure company providing the clinician network, technology, and operations that companies need to build and scale virtual care programs.
About
Wheel is a telehealth infrastructure company founded in 2017 that provides the clinical workforce, technology platform, and operational services that enable businesses to build and power virtual care programs. The company operates as a B2B platform serving healthcare companies, retailers, insurers, and employers that want to offer telehealth services without building a clinical workforce from scratch. Wheel provides access to a nationwide network of licensed clinicians including physicians, nurse practitioners, and physician assistants who can be deployed to power telehealth products across medical, behavioral health, and chronic care specialties. The platform handles clinician credentialing, scheduling, documentation workflows, and state licensure management so that clients can focus on patient experience and growth. Wheel raised over $160M and has powered telehealth programs for companies including retailers launching pharmacy and health clinics and digital health companies scaling their clinical capacity rapidly. As telehealth has become embedded in mainstream healthcare delivery, Wheel enables organizations to participate in virtual care without the complexity of building clinical operations infrastructure internally.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.